The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Hand-foot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU).
M. Dror Michaelson
No relevant relationships to disclose
Darrel P. Cohen
No relevant relationships to disclose
Sherry Li
No relevant relationships to disclose
Robert John Motzer
No relevant relationships to disclose
Bernard Escudier
No relevant relationships to disclose
Carlos H. Barrios
No relevant relationships to disclose
Patrick E. Burnett
No relevant relationships to disclose
Igor Puzanov
No relevant relationships to disclose